Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination w… Read more
Hua Medicine (Shanghai) Ltd (HUMDF) - Total Assets
Latest total assets as of June 2025: $1.42 Billion USD
Based on the latest financial reports, Hua Medicine (Shanghai) Ltd (HUMDF) holds total assets worth $1.42 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hua Medicine (Shanghai) Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Hua Medicine (Shanghai) Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hua Medicine (Shanghai) Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hua Medicine (Shanghai) Ltd's total assets of $1.42 Billion consist of 87.5% current assets and 12.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.6% |
| Accounts Receivable | $38.97 Million | 2.6% |
| Inventory | $126.67 Million | 8.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.07 Million | 1.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Hua Medicine (Shanghai) Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hua Medicine (Shanghai) Ltd's current assets represent 87.5% of total assets in 2024, a decrease from 99.0% in 2016.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2024, down from 85.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 8.3% of total assets.
Hua Medicine (Shanghai) Ltd Competitors by Total Assets
Key competitors of Hua Medicine (Shanghai) Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hua Medicine (Shanghai) Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hua Medicine (Shanghai) Ltd generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hua Medicine (Shanghai) Ltd is currently not profitable relative to its asset base.
Hua Medicine (Shanghai) Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.79 | 4.87 | 9.81 |
| Quick Ratio | 7.00 | 4.57 | 9.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.08 Billion | $ 1.21 Billion | $ 938.73 Million |
Hua Medicine (Shanghai) Ltd - Advanced Valuation Insights
This section examines the relationship between Hua Medicine (Shanghai) Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.72 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -11.5% |
| Total Assets | $1.53 Billion |
| Market Capitalization | $85.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hua Medicine (Shanghai) Ltd's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hua Medicine (Shanghai) Ltd's assets decreased by 11.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hua Medicine (Shanghai) Ltd (2016–2024)
The table below shows the annual total assets of Hua Medicine (Shanghai) Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.53 Billion | -11.48% |
| 2023-12-31 | $1.73 Billion | +53.85% |
| 2022-12-31 | $1.12 Billion | +24.12% |
| 2021-12-31 | $903.55 Million | -24.61% |
| 2020-12-31 | $1.20 Billion | -4.47% |
| 2019-12-31 | $1.25 Billion | -15.81% |
| 2018-12-31 | $1.49 Billion | +506.32% |
| 2017-12-31 | $245.78 Million | +8.40% |
| 2016-12-31 | $226.73 Million | -- |